logo
episode-header-image
Aug 2023
9m 10s

The weight-loss drug craze

Financial Times
About this episode

The UK government is pushing back against an attempt by some members of the House of Lords to close loopholes in transparency legislation, US bank stocks fell after Moody’s cut the credit ratings of 10 midsized banks, and the FT’s Jamie Smyth explains the craze behind new weight-loss drugs. 


Mentioned in this podcast:

UK government resists moves to tighten corporate transparency rules

Weak bank stocks weigh on US and European markets 

Novo Nordisk’s obesity drug cuts risk of strokes and heart attacks

Orange juice futures hit record high after storms ravage Florida crop


The FT News Briefing is produced by Fiona Symon, Sonja Hutson and Marc Filippino. Additional help from Monica Lopez, Peter Barber, Michael Lello, David da Silva and Gavin Kallmann. Topher Forhecz is the FT’s executive producer. The FT’s global head of audio is Cheryl Brumley. The show’s theme song is by Metaphor Music.


Read a transcript of this episode on FT.com


Hosted on Acast. See acast.com/privacy for more information.

Up next
Today
Martin Wolf on the US midterms: What’s the risk of political violence?
As Americans prepare to vote in the November 3 midterm elections, the FT’s chief economics commentator Martin Wolf asks what the result will mean for Donald Trump, the future of US democracy and America's place in the world. In the third of a six-part series, Martin speaks to pol ... Show More
36m 54s
Yesterday
Alphabet’s brutal day on the stock market
Alphabet’s share price fell just over 12 percent on Thursday, and UK startup Nscale is banking on a troubled US data centre project to underpin its planned $35bn IPO. Plus, we look at what’s next for the ECB now that its president Christine Lagarde announced she’s stepping down.M ... Show More
12m 15s
Oct 29
The winners and losers in the UK Budget
Chancellor John Healey has targeted banks, savers and property owners in his Autumn Budget, Benjamin Netanyahu holds the lead in Israel’s election but there’s no clear winner yet, and one of the oldest American law firms told partners that it should dissolve. Plus, the Federal Re ... Show More
13m 28s
Recommended Episodes
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s
Apr 2023
Those New Obesity Drugs Really Work–If You Can Afford Them
Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg’s Robert Langreth and Emma Court join this episode to share their reporting on recent advancements ... Show More
25m 18s
Dec 2024
A checkup on weight-loss drugs
What started as a story about Hollywood waistlines has become a global phenomenon. Weight loss drugs are becoming more and more mainstream a few years after making their dramatic debut. On this weekend episode of Reuters World News, our health reporters weigh in on the impact of ... Show More
20m 17s
Oct 2024
Hot shot: the wider promise of weight-loss jabs
<p>First they treated diabetes. Then obesity. Now <a href="https://www.economist.com/leaders/2024/10/24/its-not-just-obesity-drugs-like-ozempic-will-change-the-world?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.t ... Show More
23m 58s